 Immunotherapy with histamine dihydrochloride and low dose interleukin II, HDC Illinois II, reduces the risk of relapse in the post chemotherapy phase of acute myeloid leukemia, AML, but its clinical efficacy is primarily beneficial for patients with AML of normal cariatype. This article was authored by Marlin S. Nielsen, Alexander Horner, Matt Sproon, and others.